Modified MT-SP1 proteases that inhibit complement activation
US9795655B2 · kind B2 · utility
5Cited by
25References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 12, 2014 |
| Grant date | Oct 24, 2017 |
| Priority date | — |
| Expiry date | May 12, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y304/21109
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.